<?xml version="1.0" encoding="UTF-8"?>
<story>
  <rep id="edu.mit.story.char">
    <desc id="0" len="507" off="0">
F.H. Faulding &amp; Co., an Australian pharmaceuticals company, said its 
Moleculon Inc. affiliate acquired Kalipharma Inc. for $23 million. 
Kalipharma is a New Jersey-based pharmaceuticals concern that sells 
products under the Purepac label. 
Faulding said it owns 33 % of Moleculon's voting stock and has an 
agreement to acquire an additional 19 %. 
That stake, together with its convertible preferred stock holdings, 
gives Faulding the right to increase its interest to 70 % of Moleculon's 
voting stock.
</desc>
  </rep>
  <rep id="edu.mit.story.text">
    <desc id="1" len="507" off="0">TEXT</desc>
  </rep>
  <rep id="edu.mit.parsing.token">
    <desc id="2" len="4" off="0">F.H.</desc>
    <desc id="4" len="8" off="5">Faulding</desc>
    <desc id="6" len="1" off="14">&amp;</desc>
    <desc id="8" len="3" off="16">Co.</desc>
    <desc id="10" len="1" off="19">,</desc>
    <desc id="12" len="2" off="21">an</desc>
    <desc id="14" len="10" off="24">Australian</desc>
    <desc id="16" len="15" off="35">pharmaceuticals</desc>
    <desc id="18" len="7" off="51">company</desc>
    <desc id="20" len="1" off="58">,</desc>
    <desc id="22" len="4" off="60">said</desc>
    <desc id="24" len="3" off="65">its</desc>
    <desc id="26" len="9" off="70">Moleculon</desc>
    <desc id="28" len="4" off="80">Inc.</desc>
    <desc id="30" len="9" off="85">affiliate</desc>
    <desc id="32" len="8" off="95">acquired</desc>
    <desc id="34" len="10" off="104">Kalipharma</desc>
    <desc id="36" len="4" off="115">Inc.</desc>
    <desc id="38" len="3" off="120">for</desc>
    <desc id="40" len="1" off="124">$</desc>
    <desc id="42" len="2" off="125">23</desc>
    <desc id="44" len="7" off="128">million</desc>
    <desc id="46" len="1" off="135">.</desc>
    <desc id="49" len="10" off="138">Kalipharma</desc>
    <desc id="51" len="2" off="149">is</desc>
    <desc id="53" len="1" off="152">a</desc>
    <desc id="55" len="3" off="154">New</desc>
    <desc id="57" len="12" off="158">Jersey-based</desc>
    <desc id="59" len="15" off="171">pharmaceuticals</desc>
    <desc id="61" len="7" off="187">concern</desc>
    <desc id="63" len="4" off="195">that</desc>
    <desc id="65" len="5" off="200">sells</desc>
    <desc id="67" len="8" off="207">products</desc>
    <desc id="69" len="5" off="216">under</desc>
    <desc id="71" len="3" off="222">the</desc>
    <desc id="73" len="7" off="226">Purepac</desc>
    <desc id="75" len="5" off="234">label</desc>
    <desc id="77" len="1" off="239">.</desc>
    <desc id="80" len="8" off="242">Faulding</desc>
    <desc id="82" len="4" off="251">said</desc>
    <desc id="84" len="2" off="256">it</desc>
    <desc id="86" len="4" off="259">owns</desc>
    <desc id="88" len="2" off="264">33</desc>
    <desc id="90" len="1" off="267">%</desc>
    <desc id="92" len="2" off="269">of</desc>
    <desc id="94" len="9" off="272">Moleculon</desc>
    <desc id="96" len="2" off="281">'s</desc>
    <desc id="98" len="6" off="284">voting</desc>
    <desc id="100" len="5" off="291">stock</desc>
    <desc id="102" len="3" off="297">and</desc>
    <desc id="104" len="3" off="301">has</desc>
    <desc id="106" len="2" off="305">an</desc>
    <desc id="108" len="9" off="309">agreement</desc>
    <desc id="110" len="2" off="319">to</desc>
    <desc id="112" len="7" off="322">acquire</desc>
    <desc id="114" len="2" off="330">an</desc>
    <desc id="116" len="10" off="333">additional</desc>
    <desc id="118" len="2" off="344">19</desc>
    <desc id="120" len="1" off="347">%</desc>
    <desc id="122" len="1" off="348">.</desc>
    <desc id="125" len="4" off="351">That</desc>
    <desc id="127" len="5" off="356">stake</desc>
    <desc id="129" len="1" off="361">,</desc>
    <desc id="131" len="8" off="363">together</desc>
    <desc id="133" len="4" off="372">with</desc>
    <desc id="135" len="3" off="377">its</desc>
    <desc id="137" len="11" off="381">convertible</desc>
    <desc id="139" len="9" off="393">preferred</desc>
    <desc id="141" len="5" off="403">stock</desc>
    <desc id="143" len="8" off="409">holdings</desc>
    <desc id="145" len="1" off="417">,</desc>
    <desc id="147" len="5" off="420">gives</desc>
    <desc id="149" len="8" off="426">Faulding</desc>
    <desc id="151" len="3" off="435">the</desc>
    <desc id="153" len="5" off="439">right</desc>
    <desc id="155" len="2" off="445">to</desc>
    <desc id="157" len="8" off="448">increase</desc>
    <desc id="159" len="3" off="457">its</desc>
    <desc id="161" len="8" off="461">interest</desc>
    <desc id="163" len="2" off="470">to</desc>
    <desc id="165" len="2" off="473">70</desc>
    <desc id="167" len="1" off="476">%</desc>
    <desc id="169" len="2" off="478">of</desc>
    <desc id="171" len="9" off="481">Moleculon</desc>
    <desc id="173" len="2" off="490">'s</desc>
    <desc id="175" len="6" off="494">voting</desc>
    <desc id="177" len="5" off="501">stock</desc>
    <desc id="179" len="1" off="506">.</desc>
  </rep>
  <rep id="edu.mit.discourse.rep.refexp">
    <desc id="326" len="58" off="0">2~4~6~8~10~12~14~16~18</desc>
    <desc id="327" len="3" off="65">24</desc>
    <desc id="328" len="24" off="70">26~28~30</desc>
    <desc id="329" len="15" off="104">34~36</desc>
    <desc id="330" len="11" off="124">40~42~44</desc>
    <desc id="331" len="10" off="138">49</desc>
    <desc id="332" len="42" off="152">53~55~57~59~61</desc>
    <desc id="333" len="4" off="195">63</desc>
    <desc id="334" len="8" off="207">67</desc>
    <desc id="335" len="17" off="222">71~73~75</desc>
    <desc id="336" len="8" off="242">80</desc>
    <desc id="337" len="2" off="256">84</desc>
    <desc id="338" len="32" off="264">88~90~92~94~96~98~100</desc>
    <desc id="339" len="9" off="272">94</desc>
    <desc id="340" len="24" off="272">94~96~98~100</desc>
    <desc id="341" len="43" off="305">106~108~110~112~114~116~118~120</desc>
    <desc id="342" len="18" off="330">114~116~118~120</desc>
    <desc id="343" len="10" off="351">125~127</desc>
    <desc id="344" len="3" off="377">135</desc>
    <desc id="345" len="36" off="381">137~139~141~143</desc>
    <desc id="346" len="8" off="426">149</desc>
    <desc id="347" len="9" off="435">151~153</desc>
    <desc id="348" len="3" off="457">159</desc>
    <desc id="349" len="12" off="457">159~161</desc>
    <desc id="350" len="33" off="473">165~167~169~171~173~175~177</desc>
    <desc id="351" len="9" off="481">171</desc>
    <desc id="352" len="25" off="481">171~173~175~177</desc>
  </rep>
  <rep id="edu.mit.discourse.rep.coref">
    <desc id="353" len="460" off="0">F.H. Faulding &amp; Co.|326,327,336,337,344,346,348</desc>
    <desc id="354" len="420" off="70">Moleculon Inc. affiliate|328,339,351</desc>
    <desc id="355" len="95" off="104">Kalipharma Inc.|329,331,332,333</desc>
    <desc id="356" len="11" off="124">$23 million|330</desc>
    <desc id="357" len="8" off="207">products|334</desc>
    <desc id="358" len="17" off="222">the Purepac label|335</desc>
    <desc id="359" len="32" off="264">33 % of Moleculon's voting stock|338</desc>
    <desc id="360" len="234" off="272">Moleculon's voting stock|340,352</desc>
    <desc id="361" len="43" off="305">an agreement to acquire an additional 19 %|341</desc>
    <desc id="362" len="18" off="330">an additional 19 %|342</desc>
    <desc id="363" len="10" off="351">That stake|343</desc>
    <desc id="364" len="36" off="381">convertible preferred stock holdings|345</desc>
    <desc id="365" len="9" off="435">the right|347</desc>
    <desc id="366" len="12" off="457">its interest|349</desc>
    <desc id="367" len="33" off="473">70 % of Moleculon's voting stock|350</desc>
  </rep>
  <rep id="es.ucm.nil.indication.rep.indication">
    <desc id="368" len="58" off="0">326|NUC:DIST:2~4~6~8|MOD:DESC:12~14~16~18</desc>
    <desc id="369" len="3" off="65">327|NUC:DIST:24</desc>
    <desc id="370" len="24" off="70">328|NUC:DIST:26~28|MOD:DESC:30</desc>
    <desc id="371" len="15" off="104">329|NUC:DIST:34~36</desc>
    <desc id="372" len="11" off="124">330|NUC:DIST:40~42~44</desc>
    <desc id="373" len="10" off="138">331|NUC:DIST:49</desc>
    <desc id="374" len="42" off="152">332|MOD:DIST:53|MOD:DIST:55~57|MOD:DIST:59|NUC:DESC:61</desc>
    <desc id="375" len="4" off="195">333|NUC:DIST:63</desc>
    <desc id="376" len="8" off="207">334|NUC:DIST:67</desc>
    <desc id="377" len="17" off="222">335|MOD:DIST:71|MOD:DIST:73|NUC:DIST:75</desc>
    <desc id="378" len="8" off="242">336|NUC:DIST:80</desc>
    <desc id="379" len="2" off="256">337|NUC:DIST:84</desc>
    <desc id="380" len="32" off="264">338|NUC:DIST:88~90|MOD:DIST:92~94~96~98~100</desc>
    <desc id="381" len="9" off="272">339|NUC:DIST:94</desc>
    <desc id="382" len="24" off="272">340|MOD:DIST:94~96|MOD:DIST:98|NUC:DIST:100</desc>
    <desc id="383" len="43" off="305">341|MOD:DIST:106|NUC:DIST:108|MOD:DIST:110~112~114~116~118~120</desc>
    <desc id="384" len="18" off="330">342|MOD:DIST:114|MOD:DIST:116|NUC:DIST:118~120</desc>
    <desc id="385" len="10" off="351">343|MOD:DIST:125|NUC:DIST:127</desc>
    <desc id="386" len="3" off="377">344|NUC:DIST:135</desc>
    <desc id="387" len="36" off="381">345|MOD:DIST:137|MOD:DIST:139|MOD:DIST:141|NUC:DIST:143</desc>
    <desc id="388" len="8" off="426">346|NUC:DIST:149</desc>
    <desc id="389" len="9" off="435">347|MOD:DIST:151|NUC:DIST:153</desc>
    <desc id="390" len="3" off="457">348|NUC:DIST:159</desc>
    <desc id="391" len="12" off="457">349|MOD:DIST:159|NUC:DIST:161</desc>
    <desc id="392" len="33" off="473">350|NUC:DIST:165~167|MOD:DIST:169~171~173~175~177</desc>
    <desc id="393" len="9" off="481">351|NUC:DIST:171</desc>
    <desc id="394" len="25" off="481">352|MOD:DIST:171~173|MOD:DIST:175|NUC:DIST:177</desc>
  </rep>
</story>
